Μπορείτε να στέλνετε ειδήσεις και Δελτία Τύπου στο email μας.
Αν θέλετε να επικοινωνήσετε μαζί μας ή να στείλετε Δελτίο Τύπου πατήστε εδώ...pharmamarketingexpertsblog@gmail.com


Τρίτη 22 Δεκεμβρίου 2015

Experts predict that Pfizer will overtake Novartis in 2016






Pharmafile | Joel Levy

The year 2016 is set to see continued growth in research and development productivity, with significant new drug launches and a limited impact of patent expiries, according to a new report. The report claims blockbuster drug launches will continue to set the tone in 2016, with a dozen therapies seeking FDA approval next year. Roche is set to cement its position as one of the most efficient drug developers by having some of the biggest launches in 2016 – including the multiple sclerosis drug, ocrelizumab, developed by subsidiary Genentech.

Unlike past years, patent expiries will have minimal impact on some companies, thanks to the remaining difficulties of bringing biosimilars to the market in the US. AbbVie’s best-selling drug, Humira (adalimumab), will lose exclusivity in the US in 2016, but is not forecast to lose much of its $16 billion sales, and will remain the industry’s top seller. Despite this, investor confidence in the sector may be affected by increased scrutiny by policymakers around drug pricing and tax avoidance strategies, as seen with Pfizer’s recent takeover of Allergan and tax inversion plan.